Ouachita Baptist University

Scholarly Commons @ Ouachita
Honors Theses

Carl Goodson Honors Program

1999

Cystic Fibrosis: Biological and Ethical Considerations
Sarah Elizabeth Milam
Ouachita Baptist University

Follow this and additional works at: https://scholarlycommons.obu.edu/honors_theses
Part of the Bioethics and Medical Ethics Commons, Congenital, Hereditary, and Neonatal Diseases
and Abnormalities Commons, Medical Genetics Commons, and the Other Analytical, Diagnostic and
Therapeutic Techniques and Equipment Commons

Recommended Citation
Milam, Sarah Elizabeth, "Cystic Fibrosis: Biological and Ethical Considerations" (1999). Honors Theses.
125.
https://scholarlycommons.obu.edu/honors_theses/125

This Thesis is brought to you for free and open access by the Carl Goodson Honors Program at Scholarly
Commons @ Ouachita. It has been accepted for inclusion in Honors Theses by an authorized administrator of
Scholarly Commons @ Ouachita. For more information, please contact mortensona@obu.edu.

Cystic Fibrosis: Biological and Ethical Considerations

Sarah Elizabeth Milam

Ouachita Baptist University
Carl Goodson Honors Program
Senior Thesis
April 19, 1999

Table of Contents

BIOLOGICAL PERSPECTIVE ...... .. .... . .. ................................... . .... ... .. .... ..2
Epidemiology ....... . ................ ... .............. . ..................... .......... . .. .. .. . ... 2
Pathophysiology ...................... ........................... ......... ....... . .... .. .. ... .... 3
Diagnosis .. .................................... ...................... ... ... .. . ... .... ... .... . ..... 5
Genetics . ...................................... ... .. .. ......... ............. . .. .............. ...... 8
Molecular Basis of CF ... ................................................. ..... ... .... ... .... .. 10
Treatment ............ ..... ......................................... .... ... ... ........... ... ..... 15
GENE THERAPY ................... ......... ..... . .. ...... .. ................ .. .......... ......... 19
ETHICAL ISSUES ............................ ... .... . ....... ...... . ...... . ....... . .... . .......... 29
CONCLUSIONS ... ... ... ... ... ...... .......................................................... . .. 37
Glossary .. .. ...... ·.; .. .... . .. .. .. . .............................................. ............... . ... .. 39
Tables and Figures ...... .............................. . ................................... ....... 40

Cystic Fibrosis: Biological and Ethical Considerations

Cystic fibrosis (CF) is a progressive, multisystem disease whose etiology is a genetic
mutation in the CF gene product, cystic fibrosis transmembrane conductance regulator
(CFTR). The disorder affects all exocrine glands, with common symptoms involving the
lungs and pancreas. Although the CF gene and its protein product have been identified,
two aspects of the disease make CF particularly difficult to diagnose and manage: (a)
variability in both degree and pattern of the mutation in different individuals and (b) lack
of information regarding the precise molecular and cellular mechanisms responsible. 1 Let
us begin by examiipng the pathogenesis and pathophysiology of the disease and current
diagnosis, treatment, and research in gene therapy.

EPIDEMIOLOGY

Cystic fibrosis, the most common fatal genetic disorder among Caucasians, affects some
30,000 people in the United States. 2 The disease occurs equally in both genders and,
although most common among Caucasians, appears in virtually every race (Table 1).
One Caucasian in 28 carries the CF gene. In the United States the median survival has
increased from approximately 20 years in 1970 to 31.3 years in 1996.3 Adults with the
disease increased from 4,418 in 1986 to 7,436 in 1996.3 At the end of 1996, there were
2,274 CF patients in the United States 30-years-of-age or older and 74 patients 50-yearsof-age or older. 3 This success is likely the result of advances in diagnosis, access to
medical treatment, and respiratory therapy.2
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PATHOPHYSIOLOGY

Cystic fibrosis is characterized by disrupted function of the exocrine glands, which
release their secretions through ducts. Exocrine glands perform highly specialized
functions in a variety of organs (i.e., in the skin, respiratory tract, gastrointestinal tract,
and reproductive system); therefore, the number of possible symptoms and complications
in cystic fibrosis is large (Figure 1).

The CFTR protein acts as a chloride ion (Ci-) channel in the apical membrane of exocrine
glands and is involved in the regulation of both sodium and chloride flux. The movement
of water by osmosis across the cellular membrane is linked to ion transport. Chloride
secretion is one means of hydrating the mucosal surface of exocrine glands.4 CF patients
possess a malformed CFTR protein which causes abnormal electrolyte transportprimarily reduced ability of the membrane to excrete chloride-leading to impaired water
secretion and abnormally thick, viscous exocrine secretions. 5·6 Luminal obstruction by
highly viscous mucus and other secretions in CF is a major factor in progression of the
disease, particularly at the pulmonary and pancreatic levels. 7

The highest concentrations of CFTR are in the submucosal glands of the airways,
pancreas, salivary glands, sweat glands, intestines, and the reproductive tract. The
primary clinical manifestations of CF are concentrated in these areas and are summarized
in Figure 1. Table 2 provides a more inclusive list of the effects and complications in
each organ system, illustrating that cystic fibrosis is a multisystem disease.
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Respiratory System

The respiratory pathology of CF is in part traceable to defective clearance of thick, highly
viscous mucus from the bronchial passages, leaving the lungs susceptible to infection and
consequent inflammation. 7•8 The lower airways of patients with CF are most commonly
colonized with Staphylococcus aureus and Pseudomonas aeruginosa. 9 Repeated
bacterial, viral, and fungal infections trigger an exaggerated immune response that brings
inflammatory cells to the airways. These cells, neutrophils and macrophages, release
proteases that contribute to the destruction of lung tissue by increasing mucus secretion,
slowing the mucus-clearing movement of cilia, and directly damaging lung tissue.7

.

Respiratory disease in CF is characterized by a reduced rate of mucus clearance,
consequent accumulation of purulent sputum, recurrent respiratory infections, and
progressive loss of pulmonary function, which can ultimately result in respiratory
failure. 10 Problems in the lower respiratory tract cause more than 90 percent of the
morbidity and mortality associated with CF. 11

Digestive System

Pancreatic function becomes increasingly abnormal in most CF patients as the pancreatic
ducts become progressively obstructed by thick, viscous secretions from the exocrine
portion of the organ; pancreatic enzymes that are trapped within the ducts lead to the
autodestruction of the pancreas. 9 In 85 percent of patients with CF, partial or complete
blockage of the ducts leading from the pancreas to the small bowel results in the
impairment of fat and protein digestion and the subsequent malabsorption of nutrients. 7
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Patients are prone to failure to thrive and undernutrition, which can lead to a number of
gastrointestinal conditions (see Table 2). In advanced stages of the disease, pancreatic
fibrosis, sometimes causes obliteration of the islets of Langerhans and, consequently,
diabetes mellitus. 9 CF also affects the liver and bilary tract. Here, too, the primary
mechanism appears to be obstruction of ducts by abnormally viscid secretions. 9

Reproductive System

Except for an increase in viscosity in cervical mucus, no consistent pathologic changes
occur in the female reproductive tract in patients with CF. 9 In the male reproductive tract,

.

however, the vas deferens, seminal vesicles, or epididymides are either atretic or absent at
birth. 7 Approximately 98 percent of males with CF are infertile. 9

Sweat Glands
The sweat glands of CF patients manifest no distinctive histological changes. 9
Nonetheless, their function is abnormal. These abnormalities include reduced
reabsorption of sodium and chloride ions, leading to high concentration of these
electrolytes in sweat, causing salty sweat and excessive loss of fluid. 12 Salt depletion and
heat stroke are consequent dangers.

DIAGNOSIS

The Cystic Fibrosis Foundation National CF Patient Registry data from 1996 indicate that
the diagnosis of CF is usually made in the first year of life (71 % of cases). 13 However, in
8 percent of patients the diagnosis is not established until after 10 years of age, and the

5

diagnosis is now being made in an increasing number of adults. 13 It is essential to
confirm or exclude the diagnosis of CF in a timely fashion and with a high degree of
accuracy to avoid unnecessary testing, to provide appropriate therapeutic interventions
and prognostic and genetic counseling, and to ensure access to specialized medical
services. 14 A recent consensus document defined the specific criteria for CF diagnosis as
1) the presence of one or more typical clinical features (Table 3), 2) a history of CF in a
sibling, or 3) a positive newborn screening test result plus laboratory evidence of a CFTR
abnormality (i.e. the demonstration of an elevated [>60 mmol/L] sweat chloride
concentration). 14

Sweat Testing

Of the several methods for sweat testing, the quantitative Gibson-Cooke test is currentl y
the only uniformly accepted method. 15 A 30-minute sweat sample (?..75 mg) is obtained
by applying pilocarpine and mild electrical stimulation to a small area of the skin of the
forearm or back. The test measures the chloride and sodium levels. A sweat-chloride
concentration greater than 60 mmol/L is consistent with CF. 15

Genetic Screening

Genetic testing has made it possible for prospective parents with family histories of CF to
find out whether they are likely to be carriers of CF and to learn whether a fetus has two
mutated copies of the gene, and thus will have CF. The current general-screening test can
detect several major mutations, including 6F508, but because there are over 500 known
mutations of the CFTR gene, it is impossible at this point for laboratories to test for every
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mutation. 16 The idea of screening the general population for the CF gene is
controversial. While carrier screening has improved to 85-90 percent, most experts do
not consider this high enough to justify screening the general population. 17 There are
many questions about the usefulness and cost of screening, ethical and social
implications, insurance coverage, and how to educate and counsel people about CF.
While screening the general population is not now recommended, screening in families
with a history of CF is appropriate, in part because it is more accurate. 18

7

GENETICS

In 1936 cystic fibrosis was described for the first time by the Swiss pediatrician Guido
Fanconi. But the official history of CF began in 1938 when Dorothy Anderson, a
pediatric pathologist at the Columbia University Babies Hospital and Institute for
Pathology in New York, published the paper which provided the first comprehensive
description of the symptoms of cystic fibrosis and its effects in various organs. Anderson
also gave the disease a name, calling it "cystic fibrosis of the pancreas," on the
microscopic features she observed in pancreatic tissue. 29 By 1946 researchers deduced
that cystic fibrosis was a recessive condition after examining the pattern of disease
inheritance in famiiies. Over the next few decades extensive clinical work resulted in the
development of more accurate diagnostic methods and treatments that control the
symptoms of the disease.

The Cystic Fibrosis Gene and Its Distribution

In 1989, the gene responsible for the disease was isolated by a large group of
collaborators, led by Lap-Chee Tsui and John R. Riordan of the Hospital for Sick
Children in Toronto and by Francis S. Collins, now the Director of the Human Genome
Project at NIH.30 The CF gene codes for the cystic fibrosis transmembrane regulator
(CFTR) protein. This gene was identified with an approach known as positional cloning,
which permitted mapping of the gene without prior knowledge of the biochemical defect
through the use of polymorphic DNA markers. A single locus was found on the long arm

°

of chromosome 7. 2 Following a series of molecular cloning experiments, which included
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"chromosome walking" and "jumping," a candidate gene was identified. Formal proof
that this was the CF gene came in 1990 when a normal CFTR gene was inserted in CF
cells in vitro, resulting in the correction of the c1- secretory defect. 31

The most common CF mutation and the first to be described is a three-base pair deletion
in exon 10 that causes a deletion of the amino acid phenylalanine from position 508
(.6.F508) of the CFTR glycoprotein (Figure 2). This mutation accounts for 66 percent of
CF mutations. More than 600 mutations have now been reported, however, and the list
continues to grow. In addition, numbers of benign sequence variations have been
described. A listing of the most common mutations and their relative frequency is
included in Table 4.

Inheritance of Cystic Fibrosis

Every person has a pair of genes, one contributed by each parent, that define each
hereditary trait. Cystic fibrosis is an autosomal recessive genetic disorder. A
heterozygous individual, one with one normal and one defective copy of the gene, will
not have the disorder. These individuals are carriers of the defective gene and can pass it
to their children.. However, a homozygous person, who has received two copies of the
mutated gene (one from each parent), will have CF. So, if both parents are carriers, the
risk of having a child with CF is 1 in 4, regardless of the outcome of previous
pregnancies. The odds of a single pregnancy resulting in CF, based on the genetic status
of the parents, are shown in Figure 3.
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THE MOLECULAR BASIS OF CF

CF is attributed to abnormalities in salt metabolism due to the absence or malfunction of
the Cystic Fibrosis Transmembrane Regulator (CFTR) protein, which is essential in the
passage of the chloride ion in and out of the plasma membrane. Research and
characterization of the CFTR protein as it relates to channel regulation has given us
greater insight into the manifestations of the disease and subsequent treatment options.

Molecular Findings in CF Research

The movement of chloride across epithelial surfaces plays an important physiological role
in salt and water balance. In the infancy of CF research, it was first discovered that
individuals with CF have an elevated sweat chloride concentration. 15 Electrophysiologists
determined that some gene defect resulted in defective function of a cAMP-activated
chloride channel in epithelial cells of sweat glands and bronchial mucosa. 19 Figure 4
shows a model of this chloride channel in a cellular context. To further characterize the
chloride abnormality, several investigators studied individual chloride channel proteins
present in the plasma membranes of CF cells. An effort toward understanding the
molecular physiology of cystic fibrosis evolved from clinical observations of abnormal
glandular function to the identification of a single chloride channel abnormality in the
disease. Riordan, Tsui, and Collins employed direct molecular techniques in identifying
the gene responsible for cystic fibrosis,20 discovering that individuals with cystic fibrosis
possessed a mutation resulting in the deletion of a phenylalanine residue at position 508
(~F508).

10

The CFTR Protein

The gene responsible for CF spans 250 kilobases and contains 27 exons that, once
spliced, form a messenger RNA of approximately 6500 nucleotides encoding a 1480
amino acid polypeptide. 19 Anticipating its role, this protein was named CFTR for cystic
fibrosis transmembrane conductance regulator. The structure of the protein, shown in
Figure 5, is predicted to be a membrane glycoprotein consisting of two repeated elements,
each containing a domain capable of spanning a membrane six times (transmembrane
domain or TMD) and a region containing protein sequences known to bind nucleotides
(nucleotide-binding domain or NBD). The two halves of the protein are separated by a
large highly charged domain referred to as the regulatory or R-domain. 21 The sequence
and structure of the TMDs and NBDs are analogous to a known group of proteins called
AB Cs, or ATP-binding cassette proteins. Characteristics of this family include the ability
to bind ATP and transport substances across membranes. 21

In deducting the function of the CFTR protein, scientists had to answer one important
question: Was the CFTR a chloride channel or a regulator of chloride channels?
Subsequent investigations provided evidence that CFTR is a chloride channel. 22• 23 • 24 As
shown in Figure 6, CFTR is phosphorylated in vivo by the cAMP-dependent protein
kinase A (PKA). PKA-directed phosphorylation is a necessary priming event for channel
opening. Once phosphorylated, CFTR requires ATP binding and hydrolysis for
activation, 19 which is probably bound by NBD 1. When CFTR is activated and in the
open state, chloride movement is controlled by its own electrochemical g;radient. 2 1 That
is, no more ATP is then required because passive diffusion takes place.
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CFTR Dysfunction

The phenotype of CF arises due to a wide array of mutations, which are scattered through
the CFTR channel. Out of the approximately 500 identified CF mutations, about 67
percent of all instances of cystic fibrosis are caused by the ~F508 mutation. Four distinct
classes of mutations have been identified and are represented in Figure 7. 21

The Class I mutations are scattered throughout the CFTR gene and produce premature
termination signals because of splice site abnormalities, frameshift mutations, or
nonsense mutations. In some cases, such mutations result in an unstable mRNA and no

.

detectable protein. In other cases, a truncated protein may be synthesized and quickly
degraded. All mutants in Class I are expected to produce little or no full-length CFTR
protein, causing a loss in c1- channel function in affected epithelia. 25

The most common mutant,

~F508 ,

falls in the Class II mutations, which involve

defective protein processing. In recombinant cells, CFTR ~F508 fails to mature into the
fully glycosylated form. 25 These proteins fail to be transported to the apical membrane.
Until recently, the reason for failure had not been established. New research indicates
that the F508 deletion causes the inability of the mutant protein to fold correctly and
transit to the apical membrane. 26 Therefore, phenylalanine in position 508 makes crucial
contacts during the folding process.

Class III mutations include a defect in the nucleotide-binding domains and are seen
rarely. 25 Because the opening of the CFTR c1- channel is an energy dependent process,
the proper binding of ATP is critical. Normal regulation but reduced current flow
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characterize Class IV mutations. These mutations affect the membrane-spanning domain
of CFTR and result in reduced ion flow. 25

Genotvpe and Phenotype Correlations

The categorization of these mutations are occasionally helpful in forming a relationship
between an individual's genotype and phenotype. However, there are many unexplained
exceptions. For example, all Class I and II mutations result in a severe pancreaticinsufficient phenotype. 25 These patients have pancreatic failure, requiring pancreatic
enzyme supplementations. In contrast, Class III and IV mutations are associated with

.

less-severe phenotypes. 25 These patients retain significant pancreatic function and require
little or no pancreatic enzymes. Most dramatically, some individuals with a Class III
mutation do not exhibit classic CF symptoms at all but simply have isolated male
infertility due to the absence of the vas deferens. 27 Presumably, the differences in
phenotype relate to the degree of abnormal regulation, but its molecular basis is not yet
understood.

Physiology of Secretory Pathways Involved in Cystic Fibrosis

Transport physiology in CF has been extensively studied, especially prior to the
discovery of the CF gene. Historically, one of the first symptoms of CF is a salty taste
discovered on an infant's skin due to elevated sweat chloride concentrations. Essentially,
the secretory segment of the human sweat gland secretes isotonic NaCl, and, as this
solution transverses the distal two-thirds of the gland, NaCl is reabsorbed in excess of
H20, yielding a hypotonic sodium chloride solution, which is sweat. In CF, the defect
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lies in the distal part of the gland, and secreted NaCl is not reabsorbed, resulting in an
increased concentration of salt in the sweat. 21

More significant is the defective chloride transporter in the pancreas. Shown in Figure 8
is a model of solute transport in the pancreatic duct. Chloride is secreted by the ductal
cells through CFTR and is reabsorbed by a chloride/bicarbonate exchanger with the net
effect of bicarbonate secretion. The bicarbonate (HC03") secretion obligates sodium
movement, and thus NaHC03 appears in the ductal lumen. More importantly, the net
secretion of NaHC03 causes H20 movement across the epithelium of the duct, resulting
in isotonic pancreatic secretions. In CF, the chloride secretion through CFTR is inhibited
and results in decr~ased NaHC03 and water secretion. The latter is of particular
consequence, and ductal dehydration leads to concentration of pancreatic secretions
which accounts for the pancreatic insufficiency in CF individuals. 21 The same effect can
be seen in the epithelia of the lungs as well. An absent or malfunctioning CFTR channel
allows the chloride concentration to build up in the cell, causing water to be drawn in
from the mucus outside, which leaves the mucus thick, sticky, and prone to bacterial
infections. 28
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TREATMENT

The identification of the CF gene led to considerable progress in the understanding of the
molecular basis of cystic fibrosis and the CFTR protein. This improved understanding of
the structure and function of the protein continues to advance novel approaches toward
treatment. There is no cure for cystic fibrosis. Thus, management goals revolve around
the amelioration of the respiratory and gastrointestinal manifestations of the disease.
Although management in general consists of many components applied in combination,
some of the individual components of therapy are discussed separately below.

.

Respiratory Management

Chronic progressive pulmonary disease accounts for most of the morbidity associated
with cystic fibrosis. The goals of respiratory management are to reduce airway
obstruction by increasing the clearance of secretions and to reduce pulmonary infection.
One of the primary methods to increase mucociliary clearance in CF patients is chest
physiotherapy (CPT), which requires vigorous percussion (by using cupped hands) on the
back and chest to dislodge thick mucus from the lungs. Patients with few pulmonary
symptoms may require only a single daily treatment, but others may require three
sessions a day. 32 Since the conventional form of CPT requires someone to help with
percussion, many adolescents and adults have switched to an inflatable vest that vibrates
the chest rapidly and increases mucus clearance. 33 Patients also incorporate the use of
several types of breathing exercises to increase mucociliary clearance. Some physicians
believe that aerobic exercise can substitute for CPT. 7 However, a regular exercise
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program has not been shown to improve pulmonary function or reduce morbidity and
mortality, although it does increase maximal oxygen consumption, exercise tolerance,
respiratory muscle endurance, and psychological well-being. 34

Lung transplantation has become an accepted therapeutic option for patients with CF who
have end-stage lung disease. These patients are good candidates for transplantation if (1)
the life-threatening problems associated with CF are confined to the lungs, (2) they are
relatively young when they are considered for transplantation, and (3) they have shown
that they can comply with complex treatment regimens. Bilateral lung transplantation is
the rule, because unilateral transplants would rapidly become infected by the remaining
lung. Over 700 people with cystic fibrosis have received some form of lung transplant,
and researchers are beginning to report long-term outcomes of these procedures.
According to transplant specialists at the 11 1" Annual North American Cystic Fibrosis
Conference, survival rates are rising, infection rates are falling, post-operative exercise
performance are improving, and problems of transplant rejection are decreasing. 35 Most
patients survive the first year after surgery, and about half survive five years or longer.
Over one-third of patients are alive and doing well eight years after transplantation, and
this proportion is increasing because of improvements in techniques and treatments. The
two biggest problems facing lung transplantation for CF patients are a shortage of donor
organs and obliterative bronchiolitis (OB). About 50 percent of patients on the transplant
waiting list die before donor lungs become available. OB, which is a form of chronic
rejection, is the main cause of transplant-related disability or death that occurs years after
transplantation. 35
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Nutritional Support

Pancreatic insufficiency affects an estimated 85 percent of patients with CF and, if
untreated, results in individuals who are undernourished and, therefore, do not grow at
normal rates. 2 The mainstay in managing pancreatic insufficiency is use of pancreatic
enzymes which are ingested along with any food that contains protein, fat, or complex
carbohydrates. Other nutritional interventions include education and dietary counseling
and vitamin supplementation. Patients are encouraged to eat a normal diet to promote
adequate caloric intake with an emphasis on high fat content. They may require 120
percent to 150 percent of the Recommended Daily Allowance (RDA) for calories. Salt
supplementation is.necessary for infants, and may be used for patients who engage in
strenuous physical activity, especially in the summer. 36

Although it is true that pulmonary function is the predominant factor in determining
morbidity and mortality in CF, it is becoming increasingly clear that overall patient status
is closely tied to nutritional status. Data from the national CF Registry indicate that 40
percent of patients with CF are below the fifth percentile of weight for age and that
mortality is increased in this group. 9

Pharmacologic Therapy

Pharmacologic therapy primarily involves medications to manage the GI (Table 5) and
pulmonary (Table 6) manifestations of CF. During the past few decades of CF treatment,
antibiotics have proved to be the key element responsible for increased survival.
Antibiotics fight common pathogens such as Pseudomonas aeruginosa and
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Staphylococcus aureus that cause respiratory tract infections. Why are CF patients more
prone to bacterial infections? First, the CFTR gene defect raises salt concentrations in the
fluid lining the airways of the lung. This high salt level inactivates factors that would
normally help kill invading bacteria. The lung infections that cause so much damage in
cystic fibrosis have long been blamed on sticky mucus, which creates a comfortable place
for bacteria to nest. However, surprising new work shows that the bacteria are not just
passive guests. These bacterial agents work in three ways: (1) they interfere with the
body' s normal ways of clearing out mucus, (2) they increase production of mucus in
airways, and (3) they cause inflammation, which also increases mucus secretion. 37
Despite aggressiveyhysiotherapy and the use of antibiotics, the pulmonary status in a
patient with CF often remains impaired because of thick, viscous sputum and
bronchiectasis.

Corticosteroids and nonsteroidal anti-inflammatory drugs play a role in palliative therapy
for CF lung disease, presumably because they suppress the inflammatory response to
chronic infection that contributes to lung destruction. Bronchodilators aid in the reversal
of bronchospasms. 9 Another therapeutic approach highlighted in Table 5 involves DNA.
It was found that DNA is present in large amount in bronchiopulmonary secretions and

greatly contributes to its increased viscosity. Recombinant human deoxyribonuclease is
an enzyme that is currently being studied for its ability to digest extracellular DNA and
work to decrease mucus viscosity. 19 Basically, any therapy that improves pulmonary
status will also improve the overall health of a patient with CF.
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HUMAN GENE THERAPY
Gene therapy is the introduction of genetic material into cells for therapeutic purposes.
Gene therapy's goal is to correct the genetic source of the disease, whereas therapies
mentioned above only alleviate the symptoms. Gene therapy is a novel form of drug
delivery that enlists the patient's own cells to produce a therapeutic agent. Using the
body to treat its own disease eliminates the need for repeated administration of proteins
(as in hemophilia) or drugs (as in hereditary hypercholesterolemia) and reduces the
difficulties in complying with exogenous-drug regimens. 38 Applications of gene therapy
are not limited to rare hereditary disorders, but potentially extend to common acquired
disorders, such as cancer, heart disease, and acquired immunodeficiency syndrome.

The first approved clinical protocol for somatic gene therapy started trials in September
1990.39 Since then, more than 300 clinical protocols have been approved worldwide and
over 3000 patients have carried genetically engineered cells in their body.40 The
conclusions from these trials are that gene therapy has the potential for treating a broad
range of human diseases and that the procedures for gene delivery appear to have
relatively low adverse effects. However, the efficiency for gene transfer and expression
still remain low. Except for anecdotal reports of individual patients being helped, there is
still not conclusive evidence that a gene-therapy protocol has been successful in the
treatment of human disease.40

In this section, I hope to introduce the most common gene delivery methods and address
some of the problems faced by gene therapy. There are various categories of gene
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therapy, distinguished by the mode of delivery of the gene to the affected tissue (see Box
l). At present, gene therapy is being contemplated only on somatic (non-reproductive)
cells. Although many somatic tissues can receive therapeutic DNA, the choice of cell
usually depends on the nature of the disease. Sometimes a clear definition of the target
cell is needed. For example, the gene that is defective in CF has been identified, and
clinical trials to deliver DNA as an aerosol into the lung have already begun. Although
cystic fibrosis is manifest in this organ, it is still not clear that delivery of a correcting
gene by this method will reach the right type of cell. 41 It is also unclear how much of the
therapeutic protein or gene should be delivered.

The biggest challenge to the success of gene therapy is the development of a safe and
efficient gene delivery system. This goal is more difficult to achieve than many
investigators had predicted years ago because our immune system protects us from an
onslaught of environmental hazards, including the incorporation of foreign DNA into its
genome.

There are two categories of delivery vehicles, or vectors. The first is comprised of nonviral vectors, such as DNA mixed with polylysine or cationic lipids that allow the gene to
cross the cell membrane. Most of the current gene-therapy approaches make use of the
second category - viral vectors. Importantly, the viruses used have been disabled of any
pathogenic effects. The use of viruses is a powerful technique, because many of them
have evolved a specific machinery to deliver DNA to cells. 42 Although the viruses are
not intact, the body still recognizes them as foreign and reacts with a typical immune
response. This host response serves as a major impairment to efficient gene delivery.
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Retroviral Vectors

Retroviruses are a group of viruses whose RNA genome is converted to DNA in the
infected cell. The genome comprises three genes termed gag, pol, and env, which are
flanked by elements called long terminal repeats (LTRs). LTRs are required for
integration into the host genome and define the beginning and end of the viral genome.
They also serve as enhancer-promoter sequences - that is, they control viral gene
expression. Recombinant human CFTR cDNA is the genetic material used for CF gene
therapy. The transgene, in this case, the gene responsible for CFTR production, is
inserted into the vector. Transcription of the transgene may be under the control of viral

.

LTRs, or enhancer-promoter elements can be engineered in with the transgene.
Retrovirus vector design, production, and gene transfer is outlined in Figure 9.
Retroviruses were initially chosen as the most promising gene-transfer vehicles. 43
Currently, about 60 percent of all approved clinical protocols utilize retroviral vectors.40
Murine leukaemia virus (MuLV) has traditionally been used as the retroviral vector of
choice for clinical gene-therapy protocols. This vector can accept up to about 8 kilobases
(kb) of exogenous DNA. The use of retroviruses is advantageous because they are easily
generated, the infected viruses can be extensively characterized in tissue culture before
being injected into patients, and theoretically, the stable integration of the virus into the
host chromosome ensures its retention by the cell.

However, there are some critical limitations of retroviral vectors. One limitation is their
inability to infect non-dividing cells. This limitation can be useful in some situations, for
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example, when a toxin gene is being inserted into dividing cancer cells and not into the
normal non-dividing cells. But, most tissues in.adults, such as those that make up
muscle, brain, lung, and liver tissue, consist primarily of non-dividing cells. For this
reason, retroviruses are primarily used in ex vivo gene delivery. Another formidable
challenge is the efficiency of transplantation of the infected cells. As of now, it is not
possible to get a large number of vector particles to the desired cell type in vivo. The
viral particles would bind to as many cells they encounter and, therefore, would be
diluted out before reaching their target. What is needed is a retroviral particle that will
preferentially bind to its target cells and can be manufactured at a high titre. 40

Another problem is the possibility of the random integration of vector DNA into the host
chromosome. This could lead to the activation of oncogenes or inactivation or tumorsuppressor genes. Although the theoretical probability of such an event is quite low, it is
of some concern. 42

DNA Virus Vectors

The DNA virus used most widely for in situ gene transfer vectors is the adenovirus
(specifically serotypes 2 and 5). Adenoviral vectors have several positive attributes.
They are large and can therefore potentially hold large DNA inserts (up to 35 kb); they
are also human viruses and are able to transfect a large number of different human cell
types at a very high efficiency (often reaching nearly 100% in vitro). Adenoviruses can
insert genetic material into non-dividing cells and they can be produced at very high titres
in culture. 40 This DNA virus has been the vector of choice for several laboratories trying
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to treat the pulmonary complications of cystic fibrosis, as well as for a variety of
protocols attempting to treat cancer.

Figure 10 outlines adenovirus vector design, production, and gene transfer. These vectors
do not usually integrate into the host DNA. Instead, they are replicated as episomal
( extrachromosomal) elements in the nucleus of the host cell, thus avoiding the risks of
permanently altering the cellular genotype or of insertional mutagenosis. 44 As Figure 11
explains, the El region is deleted in the adenovirus preventing viral replication.
Expression is short-lived, usually lasting only 5-10 days.40

.

One of the main problems faced with adenoviruses is that they evoke nonspecific
inflammation and antivector cellular immunity. The immune reaction is potent, eliciting
both the cell-killing ' cellular' response and the antibody-producing ' humoral' response.
In the cellular response, virally infected cells are killed by cytotoxic T lymphocytes.

45 46
•

The humoral response results in the generation of antibodies to adenoviral proteins, and it
will prevent any subsequent infection by an adenovirus. 40 Unfortunately for gene
therapy, most of the human population will probably have antibodies to adenovirus from
previous infection with the naturally occurring virus. There are still considerable
immunological problems to be overcome before adenoviral vectors can be used to deliver
genes and produce sustained expression.

Another DNA virus used in clinical trials is the adeno-associated virus (AAV). It is a
non-pathogenic virus that is wide-spread in the human population (about 80% of humans
have antibodies directed against AAV). 40 Initial interest in AAV arose because it is the
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only known mammalian virus that shows preferential integration into a specific region in
the genome (into the short arm of human chromosome 19). Unfortunately, the present
AAV vectors appear to integrate in a nonspecific manner47 , although it has been
suggested that vectors could be designed that retain some specificity. 48

The adeno-associated virus contains two genes (cap and rep) that are sandwiched
between inverted terminal repeats that define the beginning and end of the virus. These
genes contain the packaging sequence. 49 The cap gene encodes viral capsid (coat)
proteins, and the rep gene encodes four proteins responsible for viral replication and
integration. To produce an AAV vector, the rep and cap genes are replaced with a
transgene. AAV is· often called a defective or dependent virus because it requires a helper
virus (usually adenovirus or herpes simplex virus) to generate a productive infection.so

The features that make AAV an attractive potential gene therapy vector include
nonpathogenicity, the ability to remove all of the viral genes without loss of infectivity,
and more sustained expression in non-dividing cells.so Indicators from preclinical studies
suggest that a primary difference between AAV and adenoviral vectors appears to be the
lack of immune response to AAV-transduced cells in vivo. This is due to the fact that
AA V vectors carry no viral genes, whereas current adenoviral vectors still retain about 30
kb of viral coding sequences.s1 However, latent AAV vector in the genome could
theoretically be mobilized or rescued by coincident infection by wild-type AAV and
adenovirus outbreaks in the community.s2
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A main disadvantage of the AAV vector is the fact that its genome is small, only allowing
room for about 4.8 kb of DNA. The wild-type human CFTR cDNA sequence is roughly
4.5 kb, leaving little room for promoter sequence in the AAV genome. 50 Other
limitations include vector production and purification, which are still very labor intensive.

Non-Viral Vectors

Although viral systems are potentially very efficient, two factors suggest that non-viral
gene delivery will be the preferred choice of the future: safety, and ease of
manufacturing. The most thoroughly tested nonviral vectors are based on cationic lipids.
For CF, the lipid formulations vary from study to study but have included the cationic
lipids DOTMA (N-[1-2,3-dioleyloxypropyl]-N,N,N-trimethylarnmonium chloride),
DMRIE (l,2-dimyristyloxypropyl-3-dimethylhydroxyethylarnmonium bromide) or DCCHOL (D(3PN[N'N' -dimethylarnmonoethane)carbomyl] cholesterol), complexed with
DOPE (dioleoylphosphatidylethanolamine).41 The DNA component is a plasmid
containing the CFTR cDNA with a strong heterologous promoter. These complexes
mediate gene transfer by a largely unknown mechanism. Once inside the nucleus, the
plasmid DNA most likely remains episomal.

The design and gene transfer of a typical lipid:DNA complex is shown in Figure 11.
These complexes transfect a variety of cell types, are easy to prepare, and can
accommodate and deliver genes of unlimited size.4 1 Relative to viral vectors, they are
minimally toxic, but the efficiency is much lower and the complexes are generally not
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stable. Current efforts to improve these limitations include optimization of the lipid
formulation and enhancement of the formation and stability of the lipid:DNA complex. 53

Conclusions

Almost ten years have elapsed since clinical trials for gene therapy began. The promises
are still great, but several major deficiencies still exist, including poor delivery systems,
immunological responses, and poor gene expression after genes have been delivered. All
of these problems are surmountable, but each will take time to solve (see Box 2 for
description of ideal vector). However, the logic underlying the potential usefulness of

.

human gene transfer is compelling. The Human Genome Project will provide 80,000 to
100,000 human genes that could be used for human gene transfer. Despite our present
lack of knowledge, gene therapy will almost certainly revolutionize the future practice of
medicine. The ability to give the patient therapeutic genes offers extraordinary
opportunities to treat, cure, and ultimately prevent a wide range of inherited and acquired
diseases.

26

Box I The three categories of somatic cell gene therapy
•

The first is ex vivo where cells are removed from the
body, incubated with a vector and the gene-engineered
cells are returned tot he body. This procedure is usually
done with blood cells because they are the easiest to
remove and return.

•

The second is in situ, where the vector is placed directly
into the affected tissues. Examples are the infusion of
adenoviral vectors into the trachea and bronchi of patients
with CF, the injection of a tumor mass with a vector carrying
the gene for a cytokine or a toxin, or the injection of a
vector carrying a dystrophin gene directly into the muscle
of a patient with muscu lar dystrophy

•

The third is in vivo, where a vector could be injected directly
into the bloodstream. There are no clinical examples of this
third category as yet, but if gene therapy is to fu lfill its
promise as a therapeutic option, in vivo injectable vectors
must be developed.

27

Box 2 The Ideal Vector
The ideal vector should have:
•
•

High concentration (> I 0 8 viral particles per ml) allowing many cells to be infected;
Convenience and reproducibility of production;

•
•

Ability to integrate in a site specific location in the host chromosome, or to be successfully maintained
as a stable episome;
A transcriptional unit that can respond to manipulation of its regulatory elements;

•

Ability to target the desired type of cell;

•

No components that elicit an immune response.
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ETHICAL CONSIDERATIONS

This paper has explored the use of somatic cell gene therapy (SCGT) in correcting the
CFTR defect in patients with cystic fibrosis. Somatic cell gene therapy for the treatment
of serious disease is now accepted as ethically appropriate. 40 In fact, many equate SCGT
to common replacement therapy in medicine. For example, there is no ethical difference
between injecting a diabetic with a gene for producing insulin and injecting him with
insulin itself (the gene product). The side effects from gene therapy protocols have been
so minimal that the danger now exists that genetic engineering may be used for nondisease conditions, that is for functional enhancement or cosmetic purposes.

September 1997 marked the first Gene Therapy Policy Conference organized by the
NIH Recombinant DNA Advisory Committee (RAC) which focused exclusively on the
enhancement issue. The conclusion was that enhancement engineering is inevitable and
could slip through the regulatory process if RAC and the FDA are not watchful. For
example, a US biotechnology company has developed the technology for transferring
tyronase genes into hair follicle cells. 54 Presently, they are looking for genes to promote
hair growth, specifically to reverse hair loss in cancer patients undergoing chemotherapy.
When licensing the product, the FDA would list chemotherapy-induced alopecia as the
product indication. The risk-benefit analysis would be favorable in this case. However,
once a product is licensed for any indication, it can be prescribed by physicians for any
use that is 'clinically justified. ' The result could be millions of balding men receiving
gene therapy to treat their hair loss. The conference concluded that the DNA should use a
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risk-benefit analysis that takes into account the extensive 'off-label' usage for cosmetic
reasons that could take place. 40

Using gene therapy to treat baldness is not an issue in itself, but is an example of how
some fear that society may be heading towards a 'slippery-slope' where genetic
engineering could be used for a broad range of enhancement purposes. In SCGT, the
added gene is not inherited by offspring of the patient being treated. Although I believe
this area should be approached with caution, using a risk-benefit analysis as its basis, no
argument has been provided to show why SCOT differs in any morally significant way
from cosmetic plastic surgery.ss The main concerns here should be safety issues and

.

feasibility in a time of limited medical resources. Although I may prefer that plastic
surgery be used to repair serious problems, I do not claim that plastic surgery is unethical
when used to further enhance the appearance of those without serious problems.

A far more important issue is raised by the development and use of germ-line gene
therapy (GLGT) in which eggs, sperm, or very young embryos are genetically
engineered. If preimplantation screening were to show a zygote to be positive for CF, the
parents could choose gene therapy to insert a functional allele in the stem cells. Not only
is this type of gene therapy permanent, but the transgene also becomes heritably
transmitted to future generations of the affected individual. The main concerns
surrounding GLGT fit into three categories. First is the "slippery slope" argument which
says that we should not proceed with any GLGT protocol because of the ambiguous
distinction between positive and negative gene therapy. The second concern is an
evolutionary one, arguing that elimination of certain deleterious genes, which could have
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some survival value, would eventually be detrimental to the human species. Third, there
is an iatrogenic concern, meaning that scientists who carry out GLGT to cure serious
genetic maladies may cause even greater maladies for the offspring of the treated
individual.

Positive and Negative Gene Therapy

Gene therapy used to cure or treat serious genetic maladies, such as cystic fibrosis, can be
referred to as negative gene therapy. The goal of positive gene therapy is to improve or
enhance certain characteristics, such as intelligence, in an otherwise normal individual.

When discussing p·ositive and negative gene therapy, it is most helpful to begin with a
definition of genetic malady. A generic definition by Clouser, Culver, and Gert, is as
follows:
A person has a malady if and only if he has a condition, other than his rational beliefs and
desires, such that he is suffering, or is at increased risk of suffering, a harm or an evi I (death,
pain, disability, loss of freedom or opportunity, loss of pleasure) in the absence of a distinct
sustaining cause. 56

Genetic conditions, such as CF, hemophilia, and muscular dystrophy, fit the definitional
criteria of malady. A genetic condition that does not meet the definitional criteria of a
malady should not be considered a malady, and gene therapy for such conditions
constitutes positive gene therapy. Examples of nonmaladies might include eye color,
blood type, or freckles. It is inevitable that the above definition will be vague to some
extent. Some conditions are considered " borderline" because their malady status is
questionable. Regarding a borderline condition, such as obesity, it is unclear whether the
harm suffered is universal or is primarily due to cultural conditions. Also, there is so
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little we know about the extent of environmental influence on some genetic diseases.
Even now, it is difficult to distinguish between serious disease, minor disease, and
genetic variation. Most can agree that there are extreme cases that clearly represent
serious disease. As one moves into the gray area beyond serious disease, those conditions
will not be realistic candidates for gene therapy, at least initially. 55

The fundamental concern comes down to whether positive germ line gene therapy is in
some way an unethical practice in itself. If it is not, then our society may decide that
GLGT used to enhance a child's intelligence, performance, and appearance is acceptable.
One proponent of this view is constitutional scholar John Robertson, who wrote in his
1994 work Childre·n ofChoice:
Although it may not count as part of a core procreative liberty, non-therapeutic
enhancement may nevertheless be protected. A case could be made for prenatal
enhancement as part of parental discretion in rearing offspring. If special tutors and
camps, training programs, even the administration of growth hormone to add a few
inches to height are within parental rearing discretion, why should genetic interventions to enhance normal offspring traits be any less legitimate? As long as they are
safe, effective, and likely to benefit offspring, they would no more impermissibly
objectify or commodify offspring than postnatal enhancement efforts do.57

W. French Anderson is considered to be one of the preeminent gene therapy researchers
in this country, maintaining a lab at both the NIH and UNC. He represents the other side
of the argument, strongly and repeatedly cautioning against germ-line enhancements. He
says that they do not belong in the same class as "postnatal enhancement efforts," as
ballet classes and after-school tutors. In his article published in the Hastings Center
Report, he wrote:
First, it could be medically hazardous, i.e., the risk could exceed the potential benefits and
could therefore cause harm, and second, it would be morally precarious, i.e., it would
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require moral decisions that our society is not now prepared to make and which could lead
to an increase in inequality and an increase in discriminatory practices.58

The Slippery-Slope Argument

The argument put forth by some is that, if we use negative gene therapy to cure serious
disease, we will be unable to prevent positive gene therapy from occurring. Because we
will not be able to draw a nonarbitrary line between negative and positive gene therapy,
we should protect ourselves from the latter by prohibiting the former. Those that believe
GLGT is not an acceptable method for making societal decisions see it as a "slippery
slope" to modern eugenics, which cannot be justified. The abuse of power that societies
have historically demonstrated in the pursuit of eugenic goals is well-documented. By
starting with small "improvements," some say we will slide into a new age of eugenic
thinking.

However, others including myself, hold a less extreme view. With proper education,
careful foresight, and open moratoriums, society can learn from its past and will be able
to apply genetic information and technology responsibly. I believe that gene therapy
research has, thusfar, proceeded with caution. As a society, we should be working to
prevent discrimination against individuals who do or do not elect to participate in gene
therapy.

Evolutionary Concerns

A major concern voiced by critics is evolutionary in nature. Some deleterious alleles that
would be systematically eliminated by gene therapy may have some unknown survival
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benefit to future offspring. Genetic variation affords an evolutionary advantage in
adapting to new and perhaps unforeseen conditions. A good example is found in
populations where sickle cell anemia is prevalent. An individual who is homozygous for
the recessive gene develops sickle-cell anemia. However, heterozygotes (those who carry
the sickle-cell allele and a normal allele) have a high-resistance to malaria. The relative
immunity of sickle-cell carriers to malaria is thought to occur because some of the red
blood cells of the heterozygotes are sickle-shaped, a state that inhibits infection by the
malarial parasite.

The evolutionary concern is misleading for two reasons. First, when discussing maladies

.

based on the inheritance of recessive alleles, it is important to remember that it is not the
presence of two mutant alleles that causes the malady, it is rather the absence of a normal
allele. In other words, as long as the normal allele is present, the mutant allele will have
no effect. So, as long as a normal allele is introduced into the genome, gene therapy will
work for recessive conditions. The mutant and nonfunctional genes may still remain.
Therefore, in theory, gene therapy will not lead to a loss of allelic variation.

Secondly, it seems very unlikely that there will be any serious attempt to totally eradicate
an allele from the human gene pool. The technology required will be expensive and will
probably be applied on an individual basis, with rather limited accessibility. Although
many couples might qualify for gene therapy, only a small number would elect to
participate. It is also well known that the majority of mutant alleles are kept in the gene
pool through a heterozygous carrier. There would be no reason to perform gene therapy
on heterozygotes, so the frequency of alleles would still remain at a high level. For
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example, if ge1m-line gene therapy could be developed for Tay-Sachs disease and was
used to treat all homozygous Tay-Sachs embryos (which occur at a frequency of 112000),
the frequency of the Tay-Sachs allele in the entire population would decrease only from
0.01000 to 0.0099 in one generation.

Iatrogenic Concerns

Germ line gene therapy would not only affect the treated individual, but would also affect
the individual's offspring. Since embryos cannot give informed consent, the couple
involved would be responsible. If GLGT had no associated risks, there would be no
problem with the parents giving consent. However, GLGT does carry risk that may affect

.

generations to come. There is so little we know about how genes act - a single gene can
have multiple effects on the body. Moreover, genes do not act alone. Their effects can
be amplified, diminished, or counterbalanced in ways we do not fully understand. W.
French Anderson in his article said:
Medicine is a very inexact science. We understand roughly how a simple gene works that
there are many thousands of house-keeping genes, that is, genes that do the job of running
the cell. We can predict that there are genes which make regulatory messages that are
involved in the overall control and regulation of the many housekeeping genes. Yet we
have only limited understanding of how a body organ develops into the size and shape it
does. We know many things about how the central nervous system works --- for we are
beginning to comprehend how molecules are involved in electric circuits, in memory
storage, in transmission of signals. But we are a long way from understanding thought
and consciousness. And we are even further from understanding the spiritual side of our
existence.
Even though we do not understand how a thinking, loving, interacting organism can be
derived from its molecules, we are approaching the time when we can change some of
those molecules. Might there be genes that influence the brain's organization or structure
or metabolism or circuitry in some way so as to allow abstract thinking, contemplation of
good and evil, fear of death, awe of a "God"? What if in our innocent attempts to improve
our genetic makeup we alter one or more of those genes? Could we test for the alteration?
Certainly not at present. If we caused a problem that would affect the individual or his or
her offspring, could we repair the damage? Certainly not at the present. Every parent who
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has several children knows that some babies accept and give more affection than others, in
the same environment. Do genes control this? What if these genes were accidentally
altered? How would we know if such a gene were altered?58

The list of unknown risks could not be longer. A major known risk emerges from the fact
that, with our present techniques, a transgene cannot target a specific region of
chromosome. The danger in random insertion lies in the capability of insertional
mutagenesis, which has been documented in a number of cases. In theory, the insertion
of foreign DNA may disrupt some important basic gene function if the site of insertion
were to be near or within the affected gene. If a trans gene were to be inserted near or
within a protooncogene or tumor suppressor gene, cancer could result. Even if GLGT
were to become an acceptable goal, there would have to be precise guidelines that reflect
the limitations of technology. These limitations could restrict the use of GLGT to
treating only very serious life-threatening genetic conditions.
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CONCLUSIONS

I believe that there are many convincing reasons why germ-line gene therapy should not
be pursued. First and foremost is the safety issue. We have such a lack of knowledge
about how genes work and the long-term results of gene insertion, especially regarding
the effects of protooncogenes and tumor suppressor genes. In fact there was a concern a
few years back when lymphomas developed in monkeys exposed to a retrovirus in a gene
therapy experiment. In the May, 1997, issue of Proc Natl Acad Sci USA (1997;94:5837),
Carsten Munk and colleagues from Germany, a country where gene therapy controls are
especially tight, recorded spongiform encephalomyelopathy in mice inoculated with

.

amphotrophic murine leukaemia virus. The insertional risk involved in SCGT is certainly
present, and is even greater for GLGT.

The other major concern is the possibility of using GLGT for enhancement purposes. In
a simple risk-benefit analysis, I can see no justification for using GLGT for enhancement
purposes. We might be wiJling to expose a patient to great risk to treat a grave disease,
but subjecting someone to the same risk is ethically unacceptable if the person seeking
treatment is healthy. The use of gene therapy for enhancement is only speculative and
unlikely at this time. Because genetic enhancement might reinforce irrational social
prejudices, we must look ahead and consider the social harm that might result.

I am not suggesting that germ line gene therapy should not be developed at all, just not at
this time. Now, research should be directed toward discovering the short- and long-term
effects of the gene insertion in general, and should be working toward eliminating
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iotrogenic risk. In time, like any other medical procedure, germ-line gene therapy must
be proven safe within an animal model before human trials are even considered. In the
case of grave disease, where extreme suffering and loss of life are inevitable, human trials
(to ensure the safety of the procedure) and risk associated with the procedure itself, are
both justifiable.

When considering somatic cell gene therapy, I believe that direct efforts in improving its
problematic aspects should continue. Improving vector delivery, efficacy, and safety
should remain at top priority. I see no ethical reason why SCGT should not be embraced.
However, I believe that a moratorium needs to be held to discuss issues of SCGT
enhancement. W~ need to decide what enhancements we consider unacceptable and
prevent their use. A helpful model is the moratorium that scientists imposed on
themselves in the early 1970s, when they had just discovered how to manipulate genetic
material through recombinant DNA techniques.

Genetic medicine should continue to be an empowering, not an exclusionary science. It
needs to be viewed as a clinical tool employed to help people increase their length and
quality of life, not as a public-health device designed to benefit the population. Gene
therapy has the potential to treat, cure, and ultimately prevent diseases like cystic fibro sis.
Both somatic cell and germ line gene therapy should be approached cautiously,
guidelines should be established regarding enhancement, and our long-term judgment
must not be blurred by short-term benefits.
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GLOSSARY OF ABBREVIATIONS
ATP

AAV
AV
cDNA

adenosine triphosphate ; a high energy molecule
adeno-associated virus
adenovirus
complementary DNA; used in DNA cloning, usually made
by reverse transcriptase; complementary to a given

mRNA
CF
CFTR
CPT
DC-CHOL
DMRIE
DNA
DOPE
DOTMA
Af'508

GI
kb
LTRs
MuLV
NBD
NIH
OB
PKA
RAC
RNA
RT
TMD

cystic fibrosis
cystic fibrosis transmembrane conductance regulator
chest physiotherapy
D(3 ~N[N'N' -dimethylammonoethane)-carbomyl]
cholesterol
1,2-dimyristyloxypropyl-3dimethylhydroxyethylammonium bromide
deoxyribonucleic acid
dioleoylphosphatidylethanolamine
N-[1-2,3-dioleyloxypropyl]-N,N,N-trimethylammonium
chloride
most common CF gene mutation; absence of three bases
(one cytosine and two thymines), resulting in the
deletion of phenyalanine (single letter abbreviation F) at
position
508 of the CFTR protein
gastrointestinal
kilobase; unit of measurement for genetic material
long terminal repeats; flank each end of retroviral genome
murine leukaemia virus; most common retroviral vector
used in current gene-therapy protocols
nucleotide-binding domain
national institutes of health
obliterative bronchiolitis
enzyme protein kinase A
recombinant DNA advisory committee
ribonucleic acid; genetic material from which proteins are
synthesized
reverse transcriptase; used to convert retroviral RNA to
proviral DNA
transmembrane domain
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Table 3 Phenotypic features consistent with a diagnosis of CF
1. Chronic sinopulmonary disease manifested by
a. Persistent conlonization/ infection with typical CF pathogens including
Staphylococcus aureus, nontypeable Haemophilus injluenzae, mucoid and nonmucoid
Pseudomonas aeruginosa, and Burkholderia cepacia.
b. Chronic cough and sputum production
c. Persisten chest radiograph abnomalities (e.g. bronchiectasis, atelectasis, infiltrates,
hyperinflation)
d. Airway obstruction manifested by wheezing and air trapping
e. Nasal polyps~ radiographic or computed tomographic abnormalities of the paranasal
smuses
f Digital clubbing
2. Gastrointestinal and nutritional abnormalities including:
a. Intestinal: meconium ileus, distal intestinal obstruction syndrome, rectal prolapse
b. Pancreatic: pancreatic insufficiency, recurrent pancreatitis
c. Hepatic: chronic hepatic disease manifested by clinical or histologic evidence of
focal biliary cirrhosis or multilobular cirrhosis
d. Nutritional: failure to thrive (protein-calorie malnutrition), hypoproteinemia and
edema, complications secondary to fat-soluble vitamin deficiency
3. Salt loss syndromes: acute salt depletion, chronic metabolic alkalosis
4. Male urogenital abnormalities resulting in obstructive azoospermia (CBAVD)
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Table 6

Antibiotics

aminoglycosides
(eg, to bramyc i n )

erythromycin
clindamycin

penicillins
cephalosporins

quinolones
(usually not used

in

young children)

An t i b iotics are the cornerst one for the treatment of respiratory tract i nfections
Common pathogens are Pseudomonas aeruginosa and Staphylococcus aureus; less common
are Haemophilus 1nfluenzae, Burkholderia cepacia, Candida, and Aspergillus
Once established, infection usually cannot be eradicated, only controlled
No consensus exists on the use of prophylactic antibiotics
Oral antibiotics may be used in patients with mild exacerbations, but IV therapy is
usually required
Aerosolized antibiotic therapy has recently become avai l able
Corticosteroids

hydrocortisone
prednisone
beclomethasone

triamcinolone
flunisolide
dexamethasone

Used to treat airway obstruction secondary to bronchospasm and mucosa I inflammation
Studies to date indicate that the incidence of ser i ous side effects with systemic
corticosteroids outweighs their bene fits in rou t ine use in patients with CF
Administration of corticosteroids by inhalation could mitigate thei r adverse effects; efficacy studies of inha l ed corticosteroids are under way
Alternate-day use for 1-2 years may be considered in selected patients
Bronchodi l ators
Routes of administration: ora l, subcutaneous, inhaled
Used to treat a i rway hyperactivity and to reverse bronchospasm
Whi l e common, use of bronch odilators by patients with CF remains controversial
Long -t erm benefit in CF has not been established
Cough suppressants
• Not generally used in CF because coughing is desirable to c l ear mucus
Nonsteroidal anti-inflammatory drugs ( eg, ib uprofen )
In patients with CF and mild lung i nvolvement. long-term h i gh-dose ibuprofen may slow
the progress i on o' ung disease
Lab monitoring of BUN and creatinine l evels is requi red
Mucolytic
acetylcys tein e
Inhalat i on preferred over oral route of administration, but inhaled acety lc ysteine can
trigger bronchospasm
Use in CF controversial, controlled trials i ndicate l itt le benefit
Enzyme
recombinant human deoxyribonuclease ( rhDNase )
In vitro, this enzyme decreases mucus viscosity by digesting extracellular DNA i n the mucus In
v vo, dornase alfa
Improves pulmonary function
Reduces incidence of exacerbations of infection that require parenteral antibiotics in
patients ~ 5 years of age whose FVC is~ 40% of predicted
I mproves quality o f
fe
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prolonged bleeding

Figure I . Clinical manifestations of CF
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Figure 2. The Lif508 mutation in chromosome 7 that is most commonly associated with
Cystic Fibrosis
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Figure 3. Possible outcome of a pregnancy according to the genetic status of the parents
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Figure 4. Model of cAMP-regulated chloride secretion
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Figure 5 Model of CFfR. The protein is shown inserted into a lipid bilayer. Potential
glycosylation sites are represented as branched structures on the fourth extracellular loop.
Nuclear Binding Domain (NBD) also called Nuclear Binding Fold (NBF)
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Figure 6. Multistep kinetic model of CFTR activation. Chloride channel opening
requires two step: (a) CFTR phosphorylation by cAMP-dependent PKA and (b) ATP
binding and hydrolysis. PKA = protein kinase A; PDE = phosphodiesterase; cAMP =
cyclyc AMP; P 1 = inorganic phosphate
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Figure 7. Biosynthesis and function of CFTR in an epithelial cell
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Figure 8. Cellular model of bicarbonate secretion by pancreatic duct cell.
CA= carbonic anhydrase
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Retrovirus (wild-type) RNA
Retrovirus vector RNA
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~gag I pol

't1

I env LTR
L ____ J

LTR

(normal CFTR gene)

Packaging cell
line

0
0

0

0 00

Packaged

0 retrovirus vector
0

oo

0

00

Receptor 0

. . ._

~

Pro

~RNA

j,

..... .....
..........

(CFTR protein)
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DNA
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Figure 9. Retrovirus vector design, production, and gene transfer. Retroviruses are
RNA viruses that replicate through a DNA intermediate. The gag, pol, and env
sequences are deleted from the virus rendering it replication-deficient. The expression
cassette, in this case, the CFTR gene, is inserted, and the infectious replication-deficient
retrovirus is produced in a packaging cell line that contains the gag,pol, and env
sequences that provide the proteins necessary to package the virus. The vector with its
expression cassette enters the target cell via a specific receptor. In the cytoplasm, reverse
transcriptase (RT) carried by the vector converts the vector RNA into the proviral DNA
that is randomly integrated into the target cell genome, where the expression cassette
makes its product, in the case of cystic fibrosis - the functional CFTR protein.
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Adenov1rus vector DNA

I£XPress1on
cassette
Complementing cell line

0

Oo 0

0

0

O

Adenovirus vector

0

0

Target cell

Figure 10. Adenovirus vector design, production, and gene transfer. Adenoviruses
are DNA viruses with a 36-kb genome. The wild-type adenovirus genome is divided into
early (El to E4) and late (Ll to LS) genes. All adenovirus vectors administered to
humans use adenovirus serotypes 2 or 5 as the base. The ability of the adenovirus genome
to direct production of adenoviruses is dependent on sequences in E 1. To produce an
adenovirus vector, the El sequences (and E3 sequences if the space is needed) are
deleted. The expression cassette is inserted (in our case, the CFTR gene), and the vector
DNA is transfected into a complementing cell line with El sequences in its genome. The
adenovirus vector with its expression cassette is E 1· and thus incapable of replicating.
The vector binds to the target cell through an interaction of the adenovirus fiber and
penton, each to a specific receptor, moves into a cytoplasmic endosome, and breaks out
and delivers its linear, double-stranded DNA genome with the expression cassette into the
nucleus where it functions in an epichromosomal fashion to direct the expression of its
product.
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Figure 11. Lipid:DNA complex design and gene transfer. The liposomes used in
human gene transfer trials have various compositions, but typically include synthetic
cationic lipids. The positively charged liposome is complexed to the negatively charged
plasmid with its expression cassette, in cystic fibrosis gene therapy - the CFTR gene. The
complexes enter the target cell by fusing with the plasma membrane. The vector does not
have an inherent macromolecular structure that conveys information to enable efficient
translocation of the plasmid to the nucleus. Consequently, most of the newly introduced
genetic material is wasted as it is shunted to the cytoplasmic organelles. When used in
vivo, it is likely that most, if not all, of the plasmids that reach the nucleus will function in
an epichromosomal fashion.
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